177Lu-PSMA-617 Radioligand Therapy in Patient With Prostate Cancer Sciatic Nerve Metastasis - Archive ouverte HAL
Article Dans Une Revue Clinical Nuclear Medicine Année : 2024

177Lu-PSMA-617 Radioligand Therapy in Patient With Prostate Cancer Sciatic Nerve Metastasis

Résumé

Abstract Patients with metastatic castration-resistant prostate cancer usually have lymph nodes and bone metastasis. We present a rare case of a 51-year-old patient with metastatic castration-resistant prostate cancer who complained of left truncated sciatica and diffuse bone pain and who was referred for 177 Lu-prostate-specific membrane antigen (PSMA) screening. Pretreatment 68 Ga-PSMA showed left sciatic nerve and multiple bone uptake. Patient underwent stereotactic radiotherapy on the sciatic nerve metastasis (30 Gy in 6 fractions of 5 Gy) before 7.4 GBq of 177 Lu-PSMA infusions. Left truncated sciatica disappeared after stereotactic radiotherapy. No additional toxicity was added to the sciatic nerve from 177 Lu-PSMA after stereotactic radiotherapy.

Domaines

Cancer
Fichier non déposé

Dates et versions

hal-04783223 , version 1 (14-11-2024)

Identifiants

Citer

David Tonnelet, Agathe Edet-Sanson, Laetitia Augusto, Marine Cabourg, Sébastien Thureau. 177Lu-PSMA-617 Radioligand Therapy in Patient With Prostate Cancer Sciatic Nerve Metastasis. Clinical Nuclear Medicine, 2024, 49 (12), pp.e668-e669. ⟨10.1097/RLU.0000000000005503⟩. ⟨hal-04783223⟩
11 Consultations
0 Téléchargements

Altmetric

Partager

More